Edited by one of the most influential biotechnology authorities, this second edition continues to offer answers to challenging questions while looking ahead to the future of antisense drugs, covering the fundamentals of oligonucleotide-based therapeutics and hybridization-based drugs as well as therapeutic applications for cardiovascular purposes, metabolic diseases, cancer, and neurological disorders.